Statements (60)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:acquired |
gptkb:Pernix_Therapeutics
|
gptkbp:employs |
over 1,000 people
|
gptkbp:focuses_on |
patient safety
sustainable practices cost-effective solutions therapeutic areas healthcare innovation patient-centric solutions |
gptkbp:founded |
gptkb:2009
|
gptkbp:founder |
gptkb:Robert_Wessman
|
gptkbp:global_presence |
over 35 countries
|
gptkbp:has_mission |
improve patient access to medicines
|
gptkbp:headquartered_in |
gptkb:United_States
|
gptkbp:headquarters |
gptkb:Pine_Brook,_New_Jersey
|
https://www.w3.org/2000/01/rdf-schema#label |
Alvogen
|
gptkbp:is_committed_to |
quality assurance
diversity and inclusion innovation regulatory compliance sustainability corporate social responsibility ethical business practices employee development |
gptkbp:is_involved_in |
research and development
clinical trials community outreach programs global health initiatives |
gptkbp:is_known_for |
its customer service
its competitive pricing innovative drug delivery systems high-quality generics |
gptkbp:is_recognized_for |
its innovative approaches
its commitment to quality its research capabilities |
gptkbp:marketing_strategy |
global expansion
expand its market reach |
gptkbp:members |
various pharmaceutical associations
|
gptkbp:open_to_public |
gptkb:theorem
|
gptkbp:operates_in |
gptkb:Europe
gptkb:Asia gptkb:North_America |
gptkbp:partnerships |
various healthcare organizations
|
gptkbp:production_company |
over 200 products
|
gptkbp:products |
oncology
central nervous system pain management cardiovascular |
gptkbp:receives_funding_from |
various investors
|
gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
gptkbp:specializes_in |
generic pharmaceuticals
branded pharmaceuticals |
gptkbp:subsidiary |
gptkb:Alvogen_Canada
gptkb:Alvogen_Europe gptkb:Alvogen_Korea |
gptkbp:vision |
be a leading global pharmaceutical company
|
gptkbp:bfsParent |
gptkb:Pfizer
gptkb:Schering_AG |
gptkbp:bfsLayer |
3
|